Search Results

AINN-P1: Small Model, Big IntelligenceHow does a 167M-parameter protein foundation model outperform a 650M general-purpose model on the tasks that matter?

L7 Informatics’ position is that generative AI has been deployed in regulated science with only half the architecture it needs, and that the missing half is an active knowledge graph generated at the point of execution.

In this episode of Denatured, you’ll hear from Diana Saraceni, founder and managing partner at Panakès Partners and Fabrizio Calisti, medical director at Angelini Ventures. We explore how Italy’s life sciences ecosystem has evolved over the last decade—from stronger tech transfer and growing venture capital to the gaps that still keep it from matching the UK, Germany or France in company creation and scale.

L7 Informatics CEO, Vasu Rangadass, Ph.D., examines the architectural principle separating pharmaceutical AI experimentation from enterprise-scale deployment.

Strong science, lower costs and growing capital networks are putting Spain and Portugal on the biotech investment map, even as structural bottlenecks persist, according to two investors.